false
0001864531
0001864531
2026-07-06
2026-07-06
0001864531
VSEE:CommonStock0.0001ParValuePerShareMember
2026-07-06
2026-07-06
0001864531
VSEE:WarrantsWhichEntitlesHolderToPurchaseOne1ShareOfCommonStockAtPriceOf11.50PerWholeShareMember
2026-07-06
2026-07-06
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
July 6, 2026
VSEE HEALTH,
INC.
(Exact name of registrant as specified in its charter)
| Delaware |
|
001-41015 |
|
86-2970927 |
(State or other jurisdiction
of incorporation) |
|
(Commission File Number) |
|
(I.R.S. Employer
Identification No.) |
980 N Federal Hwy #304
Boca Raton, Florida |
|
33432 |
| (Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including
area code: (561) 672-7068
N/A
(Former name or former address, if changed since
last report)
Check the appropriate box below if the Form 8-K
filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General
Instruction A.2. below):
| ☐ | Written communications pursuant to Rule 425 under the Securities
Act (17 CFR 230.425) |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange
Act (17 CFR 240.14a-12) |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b)) |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under
the Exchange Act (17 CFR 240.13e-4(c)) |
| Title of each class |
|
Trading Symbol |
|
Name of each exchange on
which registered |
| Common Stock, $0.0001 par value per share |
|
VSEE |
|
The Nasdaq Stock Market LLC |
| Warrants, which entitles the holder to purchase one (1) share of common stock at a price of $11.50 per whole share |
|
VSEEW |
|
The Nasdaq Stock Market LLC |
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933(§230.405 of this chapter) or Rule 12b-2 of the
Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check
mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting
standards provided pursuant to Section 13(a) of the Exchange Act.
Item 5.08 Shareholder Director Nominations.
To the extent applicable, the information in Item
8.01 of this Current Report on Form 8-K is incorporated by reference into this Item 5.08.
Item 8.01 Other Events.
On July 6, 2026, the board of directors (the “Board”)
of VSee Health, Inc. (the “Company”) ratified August 25, 2026 as the date of the Company’s 2026 annual meeting of stockholders
(the “2026 Annual Meeting”) and July 6, 2026 as the record date for determining stockholders who are eligible to receive notice
of and vote at the 2026 Annual Meeting. The Company will publish additional details regarding the exact time, location and matters to
be voted on at the 2026 Annual Meeting in the Company’s proxy statement for the 2026 Annual Meeting.
In order for stockholder proposals to be presented
at the 2026 Annual Meeting, including by means of inclusion of a stockholder proposal in the Company’s proxy materials under Rule
14a-8 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), the Company must receive proper notice at the
Company’s principal executive offices not later than the close of business on July 17, 2026, which the Company has determined to
be a reasonable time before it expects to begin to print and distribute its proxy materials prior to the 2026 Annual Meeting. Any such
proposal must also meet the requirements set forth in the rules and regulations of the Securities and Exchange Commission in order to
be eligible for inclusion in the proxy materials for the 2026 Annual Meeting. The July 17, 2026 deadline will also apply in determining
whether notice of a stockholder proposal is timely for purposes of exercising discretionary voting authority with respect to proxies under
Rule 14a-4(c) of the Exchange Act. In addition, pursuant to the Company’s amended and restated by-laws, for business to be properly
brought before the 2026 Annual Meeting by a stockholder, the Company must receive proper notice at the Company’s principal executive
offices not later than the close of business on July 17, 2026. In addition to satisfying the foregoing requirements, to comply with the
universal proxy rules, stockholders who intend to solicit proxies in support of director nominees other than the Company’s nominees
must provide notice that sets forth the information required by Rule 14a-19 under the Exchange Act by July 17, 2026.
All proposals must be addressed to the Secretary
and Chief Financial Officer of the Company at “VSee Health, Inc., 980 N. Federal Highway, Suite 304, Boca Raton, Florida 33432,
Attention: Secretary and Chief Financial Officer.”
SIGNATURE
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this Current Report on Form 8-K to be signed on its behalf by the undersigned hereunto
duly authorized.
| Dated: July 10, 2026 |
VSEE HEALTH, INC. |
| |
|
|
| |
By: |
/s/ Imoigele Aisiku |
| |
Name: |
Imoigele Aisiku |
| |
Title: |
Chief Executive Officer |